Abstract
BackgroundThe gastric cancer is the second most malignant tumor in the world. HER-2 is one of the key targets for the gastric cancer therapy. Anti-HER-2 antibodies like trastuzumab, exhibits the satisfactory therapeutic effect in clinical. However, the drug resistance problem limits its application.MethodIn this study, we develop a gold nanoshell (Gold Nanoshell) drug carrier for delivery and selective photo-thermal release of genes which target HER-2 and immunologic adjuvant CPG sequence in gastric tumor cells. The drug delivery system generated a multidimensional treatment strategy which includes gene-, immune- and photothermal-therapy.ResultsThe whole gold nanoshell drug delivery system exhibits the well gene transduction ability and combined treatment effect. Both in vitro and in vivo results demonstrate the multiple therapeutic effects of the drug delivery system is better than the monotherapy.ConclusionsThis study indicates the multiple combined therapy based on the gold nanoshell system would be a promising translational treatment for gastric cancer.
Highlights
The gastric cancer is the second most malignant tumor in the world, which ranks after lung cancer
This study indicates the multiple combined therapy based on the gold nanoshell system would be a promising translational treatment for gastric cancer
In this study we established a drug delivery system based on the gold nanoshell siRNA@CpG@Gold Nanoshell which colligated gene therapy, hyperthermia and immunotherapy to cope with the challenge of effective gastric cancer treatment
Summary
The whole gold nanoshell drug delivery system exhibits the well gene transduction ability and combined treatment effect. Both in vitro and in vivo results demonstrate the multiple therapeutic effects of the drug delivery system is better than the monotherapy
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have